Guardant Health
GH
NZ$83.57
Share price
-2.03%
Change (1 day)
70.60%
Change (1 year)
Categories
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.
Guardant Health (GH) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : NZ$2.65 Billion
According to Guardant Health 's latest financial reports the company's total liabilities are NZ$2.65 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Guardant Health - Total liabilities on balance sheet (from 2017 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | NZ$2.88 B | 11.96% |
| 2023-12-31 | NZ$2.57 B | 5.44% |
| 2022-12-31 | NZ$2.44 B | 6.91% |
| 2021-12-31 | NZ$2.28 B | 79.81% |
| 2020-12-31 | NZ$1.26 B | 646.59% |
| 2019-12-31 | NZ$0.17 B | 82.67% |
| 2018-12-31 | NZ$93.1 M | 92.6% |
| 2017-12-31 | NZ$48.34 M | -9.18% |
| 2016-12-31 | NZ$53.22 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Natera NTRA | NZ$0.81 B | -69.11% | 🇺🇸 USA |
 Neogen NEOG | NZ$2.28 B | -13.73% | 🇺🇸 USA |